Results 161 to 170 of about 178,855,135 (215)

Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes. [PDF]

Pharmaceuticals (Basel)
Paulo S, Laranjo M, Abrantes AM, Teixo RJ, Fonseca DA, Mendes-Abreu J, Figueiredo JP, Botelho MF, Ferreira MM, Serra A.   +9 more
europepmc   +1 more source

Possible Contribution of Oral Microbiota in the Osteonecrosis of the Jaw Induced by Zoledronate or Denosumab: A Preliminary Study. [PDF]

Biomedicines
Erovigni FM, Manca A, Moscone V, Antonucci M, Ghisetti V, Menegatti G, Chiara F, Mula J, Palermiti A, Fusco V, Bianchi L, Arduino P, D'Avolio A, Cusato J.   +13 more
europepmc   +1 more source

OSCAR-Assessing Individual Risk Profiles of MRONJ Patients. [PDF]

Clin Pract
Pitka F, Böhrnsen F.
europepmc   +1 more source

Evaluation of Osteonecrosis Risk Using Serum C-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) Levels in Osteoporotic Patients: Effects of Drug Holidays and Risk Factors. [PDF]

Eurasian J Med
Ergül EE, Laçin O, Kılıçaslan HÖ, Bostancı F, Özdemir EC, Kılıç A, Hayme S, Ayçiçek HB.   +7 more
europepmc   +1 more source

The Bisphosphonate Accumulation Index (BAI): A Quantitative Metric for Cumulative Antiresorptive Exposure in Pre-Procedural Dental and Surgical Assessment. [PDF]

Dent J (Basel)
Zecca PA, Miotto RE, Brusamolino F, Vercellini N, Serafin M, Borgese M.   +5 more
europepmc   +1 more source

Platelet-Rich Fibrin in Surgical Wound Healing of Medication-Related Osteonecrosis of the Jaw: A Pilot Clinical Study. [PDF]

Int J Mol Sci
Nowak A, Rudzka A, Skrzypczak P, Osmola K, Wyganowska ML.   +4 more
europepmc   +1 more source

Comprehensive Dental Rehabilitation in a 6-Year-Old Child with Juvenile Focal Osteoporosis Receiving IV Bisphosphonate Therapy: A Case Report. [PDF]

J Pharm Bioallied Sci
Alolayan RA.
europepmc   +1 more source

Bisphosphonate-associated osteonecrosis can hide jaw metastases [PDF]

Bone, 2007
Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatment but its pathogenesis is poorly understood. The current management of patients with bisphosphonate-associated osteonecrosis (BON) is based on "expert recommendations" and there is a recognized need of better evidence.
BEDOGNI, ALBERTO, SAIA, GIORGIA, RAGAZZO M, BETTINI G, CAPELLI P, D'ALESSANDRO E, NOCINI PF, LO RUSSO L, LO MUZIO L, BLANDAMURA, STELLA   +9 more
core   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Bisphosphonate-associated osteonecrosis of the jaw

Minerva Dental and Oral Science, 2021
The purpose of this systematic review was to determine the possible risk factors related to pathophysiology of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and identify adequate treatment strategies available and success rates.We performed a search for publications about the treatment of BRONJ, published between 2003 and 2018 in the PubMed ...
Luiz H, Ferreira Jr, Kedson D, Mendonça Jr, Jessica, Chaves de Souza, Danyella C, Soares Dos Reis, Cizelene, do Carmo Faleiros Veloso Guedes, Letícia, de Souza Castro Filice, Sérgio, Bruzadelli Macedo, Flaviana, Soares Rocha   +7 more
openaire   +2 more sources